報價延遲最少15分鐘:2025/07/21 11:51 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.57/-5.22
|
|
企業價值
41.97M
|
| 資產負債 |
|
每股賬面淨值
-0.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/21 11:51 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein. |
